Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +48.06%
#3 Akedo Akedo +42.30%
#4 Velvet Velvet +37.91%
#5 Black Phoenix Black Phoenix +34.36%
#6 Cross Cross +17.98%
#7 DoubleZero DoubleZero +17.92%
#8 Cap Cap +15.23%
#9 Tutorial Tutorial +10.61%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.25%
Coin of the day
Islamic Coin Islamic Coin
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
शेयरों में रैंक #39467
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
शेयर मूल्य
$0.11725176
अंतिम समन्वयन: 2025-07-14
मार्केट कैप
$481.50K
बदलाव (1 दिन)
-0.20%
बदलाव (1 वर्ष)
0.00%
देश
FR
व्यापार PHAXIAM Therapeutics S.A. (PHXM)

श्रेणी

Healthcare
PHAXIAM Therapeutics S.A. (PHXM) के लिए राजस्व
Jun 2024 में राजस्व TTM: $2.30M
PHAXIAM Therapeutics S.A. की नवीनतम वित्तीय रिपोर्टों के अनुसार, कंपनी की वर्तमान राजस्व (TTM) $2.30M है। 2022 में, कंपनी ने $7.13M का राजस्व अर्जित किया जो 2021 के $4.75M के राजस्व से की वृद्धि है। राजस्व वह कुल आय है जो कंपनी अपने उत्पादों या सेवाओं की बिक्री से उत्पन्न करती है। लाभ की तुलना में इसमें कोई खर्च घटाया नहीं जाता।
PHAXIAM Therapeutics S.A. के लिए 2016 से 2026 तक की राजस्व इतिहास
प्रत्येक वर्ष के अंत में राजस्व
वर्ष राजस्व परिवर्तन
2026 (TTM) $2.30M 56.82%
2023 $1.47M -79.44%
2022 $7.13M 50.00%
2021 $4.75M 4.97%
2020 $4.53M -23.61%
2019 $5.93M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
समान कंपनियों या प्रतिस्पर्धियों के लिए राजस्व
कंपनी राजस्व राजस्व में अंतर देश
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 549,098.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 261,845.69%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 439,752.28%
BE